Volunteers needed for Clean the Bay Day in Suffolk
Keep Suffolk Beautiful will participate in the 36th annual Clean the Bay Day, organized by the Chesapeake Bay Foundation, and is calling on volunteers to help clean the city's waterways and shorelines.
The event will be held from 9 a.m. to noon June 7 at two locations:
Constant's Wharf Park and Marina, 100 E. Constance Road
Sleepy Hole Park, 4616 Sleepy Hole Road
Participants will be provided with supplies including grabbers, safety vests, gloves and trash bags.
Pre-registration is not required. Volunteers can check in on-site upon arrival.
For more information, visit suffolkva.us/331/Clean-the-Bay-Day.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Look Back: Anniversary of D-Day this week
Jun. 1—This week marks 81 years since Operation Overlord — the Normandy landings in German occupied France by Allied forces during World War II — was launched on June 6, 1944. Wyoming Valley residents learned of the landings, known as D-Day, either by the crackle of a radio or the Wilkes-Barre Record newspaper with the bold headline, "Allies Invade France Across English Channel," published June 6, 1944. A large crowd gathered outside the Times Leader/Evening News/Record building on North Main Street, Wilkes-Barre, to hear reports from a radio placed in a window. Many churches and Jewish synagogues opened their doors for services with Catholic churches reciting the Holy Rosary every hour on the hour. Stores and coal collieries delayed opening, and many homes and businesses displayed the American flag upon hearing the news of D-Day. Following the Japanese attack at Pearl Harbor, Hawaii, on Dec. 7, 1941, thousands of young men enlisted at local military recruiting offices. Upon completion of basic training, those young men were put into service either in the Pacific Theatre or the European Theatre during World War II. Anxious mothers and fathers waited days to hear if their sons took part in the Normandy landings. One of the first stories involving local servicemen being involved in D-Day was published in the June 10, 1944, editions of the Times Leader and Record. U.S. Army sergeants James P. Franklin Jr., of Shickshinny, and Samuel L. Latona, of Pittston, were aboard a glider-towing twin-engine Dakota when they were shot down by German flak just off the Normandy coastline, the newspapers reported. "They made a forced landing in the English channel about 10 miles off the coast and piled into a dinghy," reported the newspapers. After several hours floating in the channel, a British destroyer rescued the two local servicemen along with the rest of their crew. In early July 1944, local newspapers began reporting those who were killed, wounded or lost on D-Day. "World War 2 has claimed the lives of two more servicemen from the area, another is reported missing in action, and four are listed as wounded in action in latest casualty announcements by the War and Navy Departments," reported the Record July 5, 1944. The first notification of killed-in-action of local servicemen were U.S. Army Pfc. George Kashula, 22, of 38 Park St., Korn Krest, Hanover Township; and U.S. Army Pfc. Bernard John Loboda, 25, of 405 S. Sherman St., Wilkes-Barre. Kashula, who served in the 453rd Quartermaster Truck Company, 5th Engineer Special Brigade; and Loboda, with the 5th Ranger Battalion, Company F, were killed on Omaha Beach on the first day of the Normandy landings.
Yahoo
18 hours ago
- Yahoo
Former nurse, 100, 'inundated' with birthday cards
A former midwife has received hundreds of cards from around the world in celebration of her 100th birthday. Bertha Preston spent time working in New Zealand, Australia and Kenya, before settling down in a nursing career at Royal United Hospital (RUH) in Bath, Somerset. With no surviving family or close friends nearby, staff at the Bloomfield Care Centre in Paulton issued a "heartfelt request" to the public to send in their warm wishes. Key worker Jane Rogers described Ms Preston as a "very strong lady", who "chose her career over marriage" and showed an unwavering dedication to her profession. Ms Preston said "her spirit remains strong and her presence continues to inspire those around her". "She's been a huge part of my life," said Ms Rogers, who has cared for Ms Preston since 2009. "All of the residents here are very special to everyone who works here, but she's a darling lady. "Because of her vulnerability and the fact she has no known family, we've all become her family, and that's how we like it." Ms Preston's "quiet strength and compassion" was born out of becoming an orphan at the age of eight, after losing her mother to tuberculosis. Her nursing journey took her around the world, most notably to Africa, where she treated patients for trachoma and helped deliver hundreds of babies. One woman wrote to Ms Preston from Kenya to ask if she had worked at the hospital during her birth in the early 1960s. "I was delighted to read of your enthusiasm for the country, and of your hard work and devotion over many years as a nurse," Sarah wrote. "You are clearly a credit to your profession." Activities assistant Christina Coles said the home had been "inundated" with letters since posting the appeal online, including a card from King Charles III and Queen Camilla. "The amount that's come through the post has been amazing," she said. "We've had such a good response, it's really been overwhelming. "It's lovely that people have made so much effort in the community to come forward for a lady who has worked so hard. "100 years is an amazing achievement for anyone. Bertha has got an incredible story and it's nice to share that with people," she added. Follow BBC Somerset on Facebook and X. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. D-Day veteran's 'unforgettable' 100th birthday World War Two decoder celebrates 100th birthday Vera celebrates 100th birthday with 450 cards Bloomfield Care Centre
Yahoo
a day ago
- Yahoo
Abortion opponents are coming for mifepristone using what medical experts call ‘junk science'
Packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023, in Rockville, Maryland. (Photo illustration by) Using flawed studies and scientific journal publications, abortion opponents are building a body of research meant to question the safety of the abortion pill mifepristone, a key target for the movement. The effort comes as federal officials have expressed a willingness to revisit the drug's approval — and potentially impose new restrictions on a medication used in the vast majority of abortions. This report was originally published by The 19th. The Illuminator is a founding member of the 19th News Network. Mainstream medical researchers have criticized the studies, highlighting flaws in their methodology and — in the case of one paper published by the conservative think tank Ethics and Public Policy Center (EPPC) — lack of transparency about the data used to suggest mifepristone is unsafe. The vast body of research shows that the drugs used in medication abortion, mifepristone and misoprostol, are safe and effective in terminating a pregnancy. 'There's a proliferation of anti-abortion propaganda right now. I think it is a coordinated attack on mifepristone,' said Ushma Upadhyay, an associate professor at the University of California, San Francisco who studies medication abortion. Released in April, the EPPC paper suggests that mifepristone results in serious adverse events for 1 in 10 patients — substantially higher than the widely accepted figure of .3 percent complication rate most research has attributed to the pill. The paper appears to count what other researchers say are non-threatening events, such as requiring follow-up care to complete the abortion, or visiting an emergency room within 45 days of an abortion — even if the patient did not end up requiring emergency care — as serious adverse effects. That paper also did not go through peer review, a standard process for scientific research in which other scholars review a study's findings and methodology before it can be published. Another paper, a commentary piece published this week in the journal BioTech, challenges the commonly cited statistic that mifepristone has a lower complication rate than acetaminophen, or Tylenol, tracing the history of the comparison and arguing that it is mathematically flawed. The paper's author, Cameron Loutitt, is a biomedical engineer by training and director of life sciences at the Charlotte Lozier Institute, a research arm of the anti-abortion group SBA Pro-Life America. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'My hope is that this paper sparks action in my peers in the research and medical community to more critically evaluate these unfounded claims regarding abortion drug safety,' Loutitt said in a statement. Days later, a group of researchers from the institute published another study, this one arguing that emergency rooms are likely to identify medication abortions as miscarriages, which they say increases the risk of needing hospital care. A miscarriage and a medication abortion are medically indistinguishable, and patients will sometimes visit an emergency room to ensure the drugs worked, or if they suspect possible complications. In places where abortion is illegal, patients may also tell health care providers they experienced a miscarriage to minimize their legal risk. Studies like the Lozier Institute paper suggest complications from medication abortions are being undercounted. That study was rejected by another journal on April 12 before being published this week, noted Upadhyay, who had served as a peer reviewer in that rejection process. A similar paper written by many of the same researchers behind the Lozier Institute's was retracted a year ago by the journal that published it, along with two others suggesting mifepristone was unsafe. 'They keep trying to publish the same junk science,' Upadhyay said. James Studnicki, the Charlotte Lozier Institute's director of data analytics, who led the second of its new anti-abortion papers and the study retracted last year, did not respond to a request for comment. But a spokesperson for the institute said the organization is challenging last year's retraction through an arbitration process. This March, Studnicki said in a statement that the retraction placed 'politics over publication ethics.' These studies and papers all fall outside the scientific consensus. More than 100 studies over decades of research have found that mifepristone — and the medication abortion regimen as a whole — has a low complication rate and is very safe to use for abortions. Papers like these aren't new, and their scientific accuracy has long been questioned. But the bevy of new reports and analyses comes at a moment when abortion opponents may have more influence in shaping public policy. Mifepristone restrictions are a top priority for the anti-abortion movement. About two-thirds of all abortions in the United States are now done using medication. Even in states with abortion bans, pregnant people have increasingly turned to abortion medication, which they receive from health providers in states with laws protecting abortion. Nationwide, about 1 in 5 abortions are now performed using telehealth; almost half of those are for people in states with bans or restrictions. Mifepristone is currently approved for use through 10 weeks of pregnancy. Health and Human Services Secretary Robert F. Kennedy Jr. testified before a Senate committee that he has directed the Food and Drug Administration to review the approval of mifepristone, citing the EPPC paper specifically. Jim O'Neill, who is nominated for a deputy secretary role, has also said he is in favor of a 'safety review' of the drug — a move that could result in new restrictions on how it is prescribed. Meanwhile, physicians and researchers are highlighting the rigor of the FDA approval process. 'FDA approval of mifepristone must reflect the rigorous clinical evidence that has proven unequivocally that it is safe and effective for use in medication,' 13 reproductive medical organizations, including the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine, said in a statement after Kennedy indicated the drug may undergo a new FDA review. 'Mifepristone has been used for decades for abortion and miscarriage management by millions of patients, and complications are exceedingly rare, minor, and most often easily treatable.' The International Institute for Reproductive Loss, an anti-abortion nonprofit, has explicitly prioritized the publication of research that supports restrictions on medication abortion. Presenting at an anti-abortion conference last September, that organization's science director, Priscilla Coleman, highlighted strategies that she said could help result in the retraction of studies showing mifepristone's safety, such as finding 'agenda-driven, poorly developed and conducted studies published in peer-reviewed journals' and writing to journal editors. Coleman did not respond to a request for comment. Though no scientific consensus has changed, anti-abortion lawmakers have rallied around the suggestion that complications are common. In a private Zoom meeting reported on by Politico, abortion opponents cited the EPPC paper as a potential tool to justify further restrictions on mifepristone — even while acknowledging that the report is 'not a study in the traditional sense' and 'not conclusive proof of anything.' Sen. Josh Hawley, a Republican from Missouri, cited the EPPC paper in a letter to FDA Commissioner Marty Makary, who had only a day before the report's publication indicated openness to reviewing mifepristone's approval if new evidence emerged. 'The time to act is now. It is time to revisit and restore the FDA's longstanding safety measures governing mifepristone,' Hawley wrote. His office did not reply to a request for further comment. 'They're producing this terrible 'science' because they don't have any real science that backs them up. And all they've gotten from the administration is, 'Yeah, we'll study it,'' said David Cohen, a law professor at Drexel University who has advised state legislatures on crafting abortion-protetctive laws. Through the courts and Trump administration, abortion opponents have pushed to reverse a 2021 FDA decision allowing mifepristone to be distributed via telehealth. In addition to calling for the in-person requirement to be reinstated, abortion opponents are asking for restrictions such as the dispensation of the drug to require three in-person visits, and for mifepristone to only be approved for use only in the first seven weeks of pregnancy. Many have also argued the drug should be taken off the market entirely. The Trump administration said on the campaign trail that it would leave abortion policy up to the states. So far, there has been little indication from the federal government that such changes are imminent. 'Pills are kind of just spreading, as we predicted, without almost any restriction and so far the anti-abortion movement hasn't figured out what to do,' Cohen said. SUPPORT: YOU MAKE OUR WORK POSSIBLE This story was originally reported by Shefali Luthra of The 19th. Meet Shefali and read more of her reporting on gender, politics and policy.
